Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
Marina Lopez-Martinez1,2, Irina Torres1,2, Sheila Bermejo1,2, 
Francesc Moreso1,2*, Clara Garcia-Carro3,4, Ander Vergara1,2, Natalia Ramos1,2, Manel Perello1,2, Alejandra Gabaldon2,5, M. Antonieta Azancot1,2, Monica Bolufer1,2, Nestor Toapanta1,2, 
Oriol Bestard1,2, 
Irene Agraz-Pamplona1,2† and 
Maria Jose Soler1,2*†- 1Department of Nephrology, Vall d’Hebron University Hospital, Barcelona, Spain
- 2Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), Vall d’Hebron University Hospital, Barcelona, Spain
- 3Department of Nephrology, San Carlos Clinical University Hospital, Madrid, Spain
- 4Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), San Carlos Clinical University Hospital, Madrid, Spain
- 5Department of Pathology, Vall d’Hebron University Hospital, Barcelona, Spain
A Corrigendum on
Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
by Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, Ramos N, Perello M, Gabaldon A, Azancot MA, Bolufer M, Toapanta N, Bestard O, Agraz-Pamplona I and Soler MJ (2022). Transpl Int. 35:10693. doi: 10.3389/ti.2022.10693
In the original article, there was a mistake in Table 1 as published. Since publication, it has been noticed that the rows “BMI (Kg/m2)” and “LDL (mg/dl)” incorrectly contained repeated data. The corrected version of Table 1 is shown below.
TABLE 1
TABLE 1. Change from baseline of analytical parameters.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: IgA nephropathy, IgAN recurrence in transplant kidney, proteinuria reduction, TRF-budesonide, CKD progression
Citation: Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, Ramos N, Perello M, Gabaldon A, Azancot MA, Bolufer M, Toapanta N, Bestard O, Agraz-Pamplona I and Soler MJ (2023) Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice. Transpl Int 35:11073. doi: 10.3389/ti.2022.11073
Received: 22 November 2022; Accepted: 07 December 2022;
Published: 05 January 2023.
Copyright © 2023 Lopez-Martinez, Torres, Bermejo, Moreso, Garcia-Carro, Vergara, Ramos, Perello, Gabaldon, Azancot, Bolufer, Toapanta, Bestard, Agraz-Pamplona and Soler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Francesc Moreso, fjmoreso@vhebron.net; Maria Jose Soler, mjsoler01@gmail.com
†These authors share senior authorship
